We are so proud and thankful for the contributions of the entire Prollenium team who helped bring this approval and are equally thrilled for the impact Revanesse® Lips™+ offers both patients and providers as a treatment option for lip augmentation,” said Ario Khoshbin, Founder and CEO of Prollenium.
TORONTO (PRWEB)
December 10, 2020
Prollenium, the manufacturer and worldwide distributor of the Revanesse® family of hyaluronic acid (HA) dermal fillers, is proud to announce the recent FDA approval of Revanesse® Lips™+ for submucosal implantation for lip augmentation in patients 22 years of age or older.
Revanesse® Lips™+ joins Revanesse® Versa™ in Prollenium’s portfolio of options for aesthetic providers and utilizes a proprietary cross-linking process which yields spherical, uniform HA particles that have a proven safety and efficacy profile. This process, along with the use of only high molecular weight HA, comprise part of the key differentiators of the Revanesse® line, which has experienced two consecutive years of record growth.
“We are so proud and thankful for the efforts and contributions of the entire Prollenium team who helped bring this approval and are equally thrilled for the impact Revanesse® Lips™+ offers both patients and providers as a treatment option for lip augmentation,” said Ario Khoshbin, Founder and CEO of Prollenium. A key addition to this latest offering is the inclusion of a 30g ultra-thin-walled needle that should help offer the desired flow characteristics for the injector and a comfortable procedure for the patient.
Prollenium is currently finalizing production and operational plans and is scheduled to launch Revanesse® Lips™+ some time in Q1 of 2021. “We want to ensure we properly execute our sales and marketing strategies with Revanesse® Versa™ for the remainder of 2020,” said President, Khasha Ighanian. The company, in partnership with their customers worldwide, remains focused on a safe and productive close to the current year with an eye towards a bright future.
Please visit RevanesseUSA.com to learn more and view Important Safety Information.
Share article on social media or email: